
|

| |
Track this Pro and follow
their portfolio moves with tickerspy™ alerts |
 |
|
 | Perceptive Advisors |
| |
Performance |
|
|
|
Similar Pro Portfolios |
|
|
|
Community |
|
| |
Today:
Week:
1-month:
All-time:
|
+1.8%
-4.7%
+3.9%
+123.3%
|
vs S&P 500:
vs S&P 500:
vs S&P 500:
vs S&P 500:
|
+1.8%
-7.2%
+4.6%
+105.5%
|
Data since: Jul-1-2007 Current Portfolio: Q1 2013
|
|
|
|
|
|
|
|
|
Share this Pro on Facebook
Share this Pro on Twitter
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |

 |
Click
a column to sort | Scroll over columns for more information |
|
|
| ACRX |
$9.60 |
0.00 |
0.00% |
|
0% |
$357.4M |
- |
323% |
-9% |
+95.5% |
$25.8M | 5.0M shares - No Change
1 Alert (0 News) - View
|
|
|
| AEGR |
$63.70 |
0.00 |
0.00% |
|
0% |
$1.8B |
- |
395% |
-16% |
+63.2% |
$136.1M | 3.4M shares - increase of 758.1K shares
No Alerts/News
|
|
|
| CELG |
$120.24 |
0.00 |
0.00% |
2,100 |
0% |
$50.2B |
- |
105% |
-9% |
+2.7% |
$12.2M | 105.0K shares - No Change
1 Alert (0 News) - View
|
|
|
| CHTP |
$2.45 |
0.00 |
0.00% |
|
0% |
$164.3M |
- |
250% |
-11% |
+20.7% |
$11.5M | 5.6M shares - New Holding
No Alerts/News
|
|
|
| CSU |
$25.44 |
0.00 |
0.00% |
|
0% |
$719.8M |
- |
163% |
-9% |
-2.3% |
$22.3M | 843.5K shares - decrease of 368.0K shares
No Alerts/News
|
|
|
| GILD |
$51.94 |
0.00 |
0.00% |
4,185 |
0% |
$79.1B |
- |
109% |
-11% |
+8.3% |
$13.5M | 276.2K shares - decrease of 10.0K shares
1 Alert (0 News) - View
|
|
|
| HCA |
$38.83 |
0.00 |
0.00% |
|
0% |
$17.3B |
- |
62% |
-7% |
-4.6% |
$15.4M | 380.0K shares - decrease of 197.5K shares
No Alerts/News
|
|
|
| INFI |
$19.46 |
0.00 |
0.00% |
5,200 |
0% |
$930.7M |
- |
54% |
-61% |
-60.7% |
$133.3M | 2.7M shares - increase of 204.5K shares
2 Alerts (0 News) - View
|
|
|
| NBIX |
$12.70 |
0.00 |
0.00% |
|
0% |
$847.2M |
- |
89% |
-10% |
+7.6% |
$53.5M | 4.4M shares - increase of 310.5K shares
No Alerts/News
|
|
|
| NEPT |
$2.98 |
0.00 |
0.00% |
|
0% |
$179.0M |
- |
84% |
-42% |
+15.1% |
$13.9M | 5.5M shares - decrease of 100.0K shares
No Alerts/News
|
|
|
| QCOR |
$45.93 |
0.00 |
0.00% |
|
0% |
$2.7B |
2.2% |
166% |
-22% |
+46.3% |
$14.5M | 446.0K shares - increase of 406.0K shares
1 Alert (0 News) - View
|
|
|
| REGN |
$242.76 |
0.00 |
0.00% |
|
0% |
$23.7B |
- |
126% |
-15% |
+36.0% |
$11.5M | 65.0K shares - New Holding
1 Alert (0 News) - View
|
|
|
| SHPG |
$98.31 |
0.00 |
0.00% |
|
0% |
$18.4B |
0.5% |
23% |
-4% |
+8.0% |
$19.3M | 210.8K shares - increase of 30.8K shares
No Alerts/News
|
|
|
| SRPT |
$38.15 |
0.00 |
0.00% |
8,049 |
1% |
$1.2B |
- |
1056% |
-15% |
+6.6% |
$99.3M | 2.7M shares - increase of 1.4M shares
No Alerts/News
|
|
|
| VPHM |
$28.69 |
0.00 |
0.00% |
|
0% |
$1.8B |
- |
47% |
-9% |
+15.8% |
$19.0M | 756.3K shares - increase of 70.0K shares
No Alerts/News
|
|
|
|
|
Discuss Perceptive Advisors's portfolio
|
|
|
|
| |

|
| |
|
| |

|
| |
Growing Uses For $4B-a-Year Gilead HIV Drugs GILD
Linked by YCHARTS ( track newsfeed | ignore newsfeed ) - June 13, 01:32PM from (ycharts.com) Less than a year after the FDA endorsed the notion of using medications to prevent HIV, a new study has found using the Viread
Flag
Post a comment
Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains CELG BIIB VRTX GILD ALXN ONXX OREX TSRX
Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - June 13, 08:15AM from (247wallst.com) The higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios.
Flag
Post a comment
Gilead's Viread Reduces HIV Risk for Drug Users in Study GILD
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - June 12, 03:03PM from (www.bloomberg.com) Gilead Sciences Inc. (GILD)’s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in
Flag
Post a comment
Short Interest Falls in Vertex, Rises in Biogen Idec BMY PFE MRK AMGN CELG REGN BIIB VRTX VVUS GILD ALXN PCYC ONXX ARNA DNDN ILMN NVS
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - June 12, 01:29PM from (www.benzinga.com) Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest
Flag
Post a comment
Wall Street Rebounds CTB CELG FCX FSLR
Linked by NYTimes ( track newsfeed | ignore newsfeed ) - June 12, 09:55AM from (www.nytimes.com) Stocks were higher Wednesday, recovering after a sell-off in the previous session, even as questions lingered over how soon
Flag
Post a comment
ClearLight Partners Agrees to Sale of The Outsource Group HCA
Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - June 12, 09:02AM from (www.businesswire.com) ClearLight Partners, LLC has entered into a definitive agreement to sell The Outsource Group, Inc. (“TOG”) to Parallon
Flag
Post a comment
Celgene Announces Additional $3.0 Billion Share Repurchase Program CELG
Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - June 12, 08:00AM from (www.businesswire.com) Celgene Corporation (NASDAQ: CELG) announced today that its Board of Directors authorized the repurchase of up to an additional
Flag
Post a comment
Mid-Day Market Update: Stocks Pare Losses, Navistar Drops On Q2 Results DOLE CI NAV QCOR XTEX CTRX LULU
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - June 11, 12:38PM from (www.benzinga.com) Midway through trading Tuesday, the Dow traded down 0.01 percent to 15,237.32 while the NASDAQ dropped 0.27 percent to 3,464.43.
Flag
Post a comment
Questcor Adds Former Shire CEO To Board QCOR
Linked by The Dividend Daily ( track newsfeed | ignore newsfeed ) - June 10, 10:21PM from (www.dividend.com) Today, Questcor Pharmaceuticals Inc (QCOR) announced its newest addition to its board of directors: former CEO of Shire PLC,
Flag
Post a comment
Gilead's Hepatitis C Drug to Get Priority Review by FDA BMY GILD ABBV
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - June 07, 06:03PM from (www.bloomberg.com) Gilead Sciences Inc. (GILD), the world’s largest maker of HIV medicines, said its experimental hepatitis C pill, sofosbuvir,
Flag
Post a comment
Drug Company Profits Set to Increase from Additions to DSM-5 LLY PFE SHPG NVS
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - June 06, 08:59AM from (www.benzinga.com) It’s a simple matter of math. The more diseases there are to treat, the more profit there is to be made – by drug companies
Flag
Post a comment
Mid-Day Market Update: Stocks Pare Gains, G-III Apparel Surges On Q1 Results DG GIII ARRY CRM INFI SLCA ET
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - June 04, 01:24PM from (www.benzinga.com) Midway through trading Tuesday, the Dow traded up 0.01 percent to 15,256.10, while the NASDAQ rose 0.24 percent to 3,473.61.
Flag
Post a comment
Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings MNKD CLP MAA BMRN DSGX CBRL INFI
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - June 03, 10:34AM from (www.benzinga.com) Following the market opening Monday, the Dow traded up 0.69 percent to 15,220.16, while the NASDAQ rose 0.12 percent to 3,460.18.
Flag
Post a comment
Drugs Go From Hit to Dud in Two Years in Hepatitis Race BMY JNJ MRK VRTX GILD ABBV
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - June 03, 03:37AM from (www.bloomberg.com) Jean-Michel Pawlotsky has déjà vu.
The doctor in the town of Creteil, just outside Paris, is telling hepatitis C
Flag
Post a comment
|
|